NPCE

NeuroPace, Inc.

Investor Moves

NameValueActionChangePriceLast Price
Steven CohenPoint72
$2M152k shares
AddQ1 2026
$2M
$13.15
$16.08
Paul Tudor Jones IITudor Investment
$2M135.7k shares
TrimQ1 2026
$1M
$13.15
$16.08
Ken GriffinCitadel Advisors
$1M87.3k shares
TrimQ1 2026
$888k
$13.15
$16.08
Jim SimonsRenaissance Technologies
$2M174.3k shares
TrimQ1 2026
$1M
$13.15
$16.08
Ken GriffinCitadel Advisors
$1.8M
AddQ4 2025
$2M
--
$16.08
Jim SimonsRenaissance Technologies
$2.1M
AddQ4 2025
$2M
--
$16.08

Insider Trades

NameValueActionPriceLast Price
Morrell MarthaCHIEF MEDICAL OFFICER
$399k25k shares
SellDec 15, 2025
$15.97
$16.08

News

zacks.comNPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsyzacks.comJun 2businesswire.comNeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meetingbusinesswire.comMay 29businesswire.comNeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Carebusinesswire.comMay 29zacks.comIs NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?zacks.comMay 27zacks.comNPCE Explains How NeuroPace's RNS System Makes Moneyzacks.comMay 27